Last reviewed · How we verify
insulin lispro injection, exenatide injection
This combination uses insulin lispro to lower blood glucose by promoting cellular glucose uptake, and exenatide to stimulate insulin secretion and slow gastric emptying in response to meals.
This combination uses insulin lispro to lower blood glucose by promoting cellular glucose uptake, and exenatide to stimulate insulin secretion and slow gastric emptying in response to meals. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | insulin lispro injection, exenatide injection |
|---|---|
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Drug class | Insulin analog + GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells, facilitating glucose uptake and lowering blood glucose levels. Exenatide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, inhibits glucagon release, and slows gastric emptying, thereby reducing postprandial glucose excursions. Together, they provide complementary glucose-lowering effects for improved glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nausea
- Vomiting
- Injection site reactions
- Headache
Key clinical trials
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PHASE3)
- Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy (PHASE4)
- A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes (PHASE3)
- Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients (PHASE4)
- Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: